First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

计划入组 50 人 · 首次发布于 2017 年 10 月 20 日

A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis

计划入组 39 人 · 首次发布于 2018 年 10 月 3 日

A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)

计划入组 144 人 · 首次发布于 2020 年 5 月 20 日

AMY-106

AMY-109

AMY-301

Finkelstein, Amy

United States

AMY ANNE ANDREWS

Australia

iFreeETF US Treasury Bond 7-10 Year Hdg

United States

Novartis Reports Positive Phase III Results for Fabhalta in Rare Kidney Disease C3 Glomerulopathy

4basebio Appoints Amy Walker as CEO to Lead Commercial Growth in Synthetic DNA Manufacturing

VISIBLE Study Shows Guselkumab Effective for Psoriasis in Skin of Color Patients